Weekly PMCC Update – Pfizer Inc. (PFE)

Date: February 20, 2026
Position Status: Open (5 Contracts)
Days to March Expiration: 14 DTE


📊 Where the Trade Stands Now

Two weeks into the position, the structure is doing exactly what it’s supposed to do.

Current Snapshot (Approximate):

  • Stock Price: ~$26.41
  • Net Position P/L: +$920
  • Return on Capital: ~30.7%
  • Short Call (Mar 6 $27.50): Now trading around $0.16
  • Premium Captured So Far: ~46% of max on this cycle
  • DTE Remaining: 14 days

We opened this PMCC for a $6.00 net debit, and at this point the diagonal is working in our favor. The short call has decayed nicely while the LEAP continues to provide strong directional exposure.


🎯 What’s Working

1️⃣ Time Decay Is Paying

We sold the March $27.50 call for $0.30.
With it now near $0.16, nearly half the premium has already decayed — and we still have two weeks left.

This is textbook PMCC behavior:

  • Stock stays below resistance
  • Short call bleeds value
  • LEAP holds intrinsic strength

2️⃣ Structure Is Intact

PFE is still well above the $20 LEAP strike, which keeps the core bullish structure healthy.

No earnings pressure this week.
No volatility shock.
No gamma stress.

This is exactly the type of calm environment where diagonals quietly compound.


📈 Greeks Check (Big Picture)

  • Long LEAP delta remains strong (deep ITM)
  • Short call delta still manageable
  • Net position still behaves like ~synthetic long exposure
  • Gamma risk remains low as long as price stays under $27.50

We are not near the danger zone yet.


🧠 Decision Framework – Next 14 Days

We now enter the most important phase of the cycle.

If PFE stays below $27.50:

Ideal outcome.
Let decay continue and target:

  • 60–70% max profit before closing early
    or
  • Allow full expiration if comfortably OTM

If PFE pushes toward $27.50–$28:

That’s the gamma test zone.
I will:

  • Roll the short call up and out (likely $28–$30)
  • Take credit
  • Restore upside runway

If PFE drifts lower (<$25):

Short call decays faster.
Income mode improves.
LEAP softens but structure remains fine.


📌 Key Observations This Week

  • No assignment risk currently.
  • Extrinsic decay is occurring steadily.
  • No need for intervention.
  • Position behaving exactly according to plan.

This is why I structure these trades with rules in advance — so I’m not reacting emotionally to small price moves.


🔐 Rule Reminder

  • Do not let short calls expire ITM.
  • Manage based on net liquidation value.
  • Ignore individual leg P/L.
  • Focus on structure, not noise.

💰 Capital Efficiency Check

Initial capital deployed: ~$3,150
Current open gain: ~$920

That’s strong early-cycle performance with 14 days still remaining in the short leg.

This is why the PMCC works:

  • Controlled directional exposure
  • Systematic income
  • Defined repair plan
  • No panic management

🔎 Overall Assessment

This trade is currently in the “quiet compounding” phase.

Nothing to fix.
Nothing to force.
Just let time do its job.

If the stock cooperates for another week, we may be looking at closing early and redeploying into the next income cycle.

That’s the goal — repeatable, structured income without over-managing.

I’ll update again next week as we approach the final stretch of this March cycle.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *